russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-2110Research ArticleКЛИНИКА И ФАРМАЦИЯCLINIC AND PHARMACOLOGYЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ТЕРАПИИ ЭПРОСАРТАНОМ С ПОЗИЦИЙ «МЕДИЦИНЫ ДОКАЗАТЕЛЬСТВ»EFFICACY AND SAFETY OF EPROSARTAN THERAPY AS ASSESSED FROM THE STANDPOINT OF EVIDENCE-BASED MEDICINEВерткинА. Л.VertkinA. L.

Кафедра клинической фармакологии и внутренних болезней

ТополянскийА. В.TopolianskyA. V.

Кафедра клинической фармакологии и внутренних болезней

Московский государственный медико-стоматологический университетRussian Federation200128082001046366Copyright © Верткин А.Л., Тополянский А.В., 20012001Верткин А.Л., Тополянский А.В.Vertkin A.L., Topoliansky A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2110

Эффективность и безопасность терапии эпросартаномс позиций «медицины доказательств».

Efficacy and safety of eprosartan therapy as assessed from the standpoint of evidence-based medicine.

ReferencesHarron D.W.G., Brogden R.N. Propafenone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cardiac arrhythmias. – Drugs, 1987; 34: 617-647.Harron D.W.G., Brogden R.N. Propafenone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cardiac arrhythmias. – Drugs, 1987; 34: 617-647.Funck-Bentano C., Kroemer H.K., Lee J.T., Roden D.M. Propafenone. – New Engl. J. Med., 1990; 322: 518-525.Funck-Bentano C., Kroemer H.K., Lee J.T., Roden D.M. Propafenone. – New Engl. J. Med., 1990; 322: 518-525.Veale D., McComb J.M., Gibson G.J. Propafenone. – Lancet, 1990; 335: 979-985..Veale D., McComb J.M., Gibson G.J. Propafenone. – Lancet, 1990; 335: 979-985..Bryson H.M., Palmer K.J., Langtry H.D. et al. Propafenone: a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. – Drugs, 1993; 45 (1): 85-130.Bryson H.M., Palmer K.J., Langtry H.D. et al. Propafenone: a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. – Drugs, 1993; 45 (1): 85-130.Hii J.T.Y., Duff H.J., Burgess E.D. Clinical pharmacokinetics of propafenone. – Clin. Pharmacokinetics, 1991; 21: 1-10.Hii J.T.Y., Duff H.J., Burgess E.D. Clinical pharmacokinetics of propafenone. – Clin. Pharmacokinetics, 1991; 21: 1-10.Axelson J.E., Chan G.L-Y., Kirsten E.B. et al. Food increase the bioavalability of propafenone. – Brit. J. Clin. Pharmacol., 1987; 23: 735-741.Axelson J.E., Chan G.L-Y., Kirsten E.B. et al. Food increase the bioavalability of propafenone. – Brit. J. Clin. Pharmacol., 1987; 23: 735-741.Latini R., Marchi S., Riva E. et al. Distribution of propafenone and its active metabolites, 5-hydroxypropafenone. – Amer. Heart. J., 1987; 113: 843-846.Latini R., Marchi S., Riva E. et al. Distribution of propafenone and its active metabolites, 5-hydroxypropafenone. – Amer. Heart. J., 1987; 113: 843-846.Boriani G., Strocchi E., Capucci A. et al. Relationships between debrisoqiune hydroxylation and propafenone pharmacokinenics. – Drug Invest., 1990; 2 (2): 114-119.Boriani G., Strocchi E., Capucci A. et al. Relationships between debrisoqiune hydroxylation and propafenone pharmacokinenics. – Drug Invest., 1990; 2 (2): 114-119.Kalow W. Ethnic differences of drug metabolism. – Drugs, 1982; 7: 373-400.Kalow W. Ethnic differences of drug metabolism. – Drugs, 1982; 7: 373-400.Siddoway L.A., Thompson K.A., McAliister C.R. et al. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences. – Circulation, 1987; 75: 785-791.Siddoway L.A., Thompson K.A., McAliister C.R. et al. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences. – Circulation, 1987; 75: 785-791.Lee J.T., Kroemer H.K., Silberstein D.J. et al. The role of genetically determined polymorphic drug metabolism in the b-blockade produced by propafenone. – New Engl. J. Med., 1990; 322: 1764- 1768.Lee J.T., Kroemer H.K., Silberstein D.J. et al. The role of genetically determined polymorphic drug metabolism in the b-blockade produced by propafenone. – New Engl. J. Med., 1990; 322: 1764- 1768.Kessler J.M., Cubeddu L.X. Cardiovascular therapy in patients with organ failure. – In: F.H.Messerli (ed.) Cardiovascular drug therapy. – 2nd ed. – Philadelphia, 1996. – pp. 234-250.Kessler J.M., Cubeddu L.X. Cardiovascular therapy in patients with organ failure. – In: F.H.Messerli (ed.) Cardiovascular drug therapy. – 2nd ed. – Philadelphia, 1996. – pp. 234-250.Reiffel J.A., Murray K.T., Prystowsky E.N. Propafenone. — In: F.H.Messerli (ed.) Cardiovascular drug therapy. – 2nd ed. – Philadelphia, 1996. – pp. 1349-1362.Reiffel J.A., Murray K.T., Prystowsky E.N. Propafenone. — In: F.H.Messerli (ed.) Cardiovascular drug therapy. – 2nd ed. – Philadelphia, 1996. – pp. 1349-1362.Seipel L., Breihard G. Propafenone – a new antiarrhythmic drug. — Europ. Heart J., 1980; 1:309-313.Seipel L., Breihard G. Propafenone – a new antiarrhythmic drug. — Europ. Heart J., 1980; 1:309-313.Dukes I.D., Vaughan-Williams E.M. The multiple modes of action of propafenone. – Europ. Heart J., 1984; 5 (1):115-125.Dukes I.D., Vaughan-Williams E.M. The multiple modes of action of propafenone. – Europ. Heart J., 1984; 5 (1):115-125.Podrid P.J., Lown B. Propafenone – a new drug for ventricular arrhythmias – J. Amer. Coll.. Cardiol., 1984; 4: 117-125.Podrid P.J., Lown B. Propafenone – a new drug for ventricular arrhythmias – J. Amer. Coll.. Cardiol., 1984; 4: 117-125.Valderrabano M., Singh B.N. Electrophysiologic and antiarrhythmic effect of propafenone: Focus on atrial fibrillation. – J.Cardiovasc. Pharmacol. Ther., 1984; 4: 183-198.Valderrabano M., Singh B.N. Electrophysiologic and antiarrhythmic effect of propafenone: Focus on atrial fibrillation. – J.Cardiovasc. Pharmacol. Ther., 1984; 4: 183-198.Shen E.N. Propafenone: a promising new antiarrhythmic agent. – Chest, 1990; 98: 434-441.Shen E.N. Propafenone: a promising new antiarrhythmic agent. – Chest, 1990; 98: 434-441.Woosley R.L. Antiarrhythmic drugs. – Annu. Rev. Pharmacol. Toxicol., 1991; 31: 427-455.Woosley R.L. Antiarrhythmic drugs. – Annu. Rev. Pharmacol. Toxicol., 1991; 31: 427-455.Kowey P.R. Pharmacological effects of antiarrhythmic drugs. Review and update. – Arch. Intern. Med., 1998; 158 (4): 325-332.Kowey P.R. Pharmacological effects of antiarrhythmic drugs. Review and update. – Arch. Intern. Med., 1998; 158 (4): 325-332.Thompson K.A., Iansmith D.H., Siddoway L.A. et al. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinji fibers. — J. Pharmacol. Exper. Ther., 1988; 244: 950-955.Thompson K.A., Iansmith D.H., Siddoway L.A. et al. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinji fibers. — J. Pharmacol. Exper. Ther., 1988; 244: 950-955.Zipes D.P. Management of cardiac arrhythmias: Pharmacological, electrical and surgical techniques. – In: E.Braunwald (ed.) Heart disease. – 5th edition,- Philadelphia, 1997. – pp. 593-639.Zipes D.P. Management of cardiac arrhythmias: Pharmacological, electrical and surgical techniques. – In: E.Braunwald (ed.) Heart disease. – 5th edition,- Philadelphia, 1997. – pp. 593-639.Haefeli E.W., Vozeh S., Huy-Rriem H., Follath F. Comparison of pharmacodynamic effects of intravenous and oral propafenone. – Clin. Pharmacol. Therapy, 1990; 48: 245-254.Haefeli E.W., Vozeh S., Huy-Rriem H., Follath F. Comparison of pharmacodynamic effects of intravenous and oral propafenone. – Clin. Pharmacol. Therapy, 1990; 48: 245-254.Horowitz L.N. Current management of arrhythmias. – Philadelphia, 1991. – pp. 357-364.Horowitz L.N. Current management of arrhythmias. – Philadelphia, 1991. – pp. 357-364.Prystowsky E.N., Heger J.J., Chilson D.A. et al. Antiarrhythmic and electrophysiologic effects of oral propafenone. — Amer. J. Cardiol., 1984; 54: 26D-28D.Prystowsky E.N., Heger J.J., Chilson D.A. et al. Antiarrhythmic and electrophysiologic effects of oral propafenone. — Amer. J. Cardiol., 1984; 54: 26D-28D.Goy J.-J., Fromer M,., Kappenberger L. Electrophysiologic effects of intravenous propafenone at rest, during isoproterenol infusion and during exercise in the Wolff-Parkinson-White syndrome. – Amer. J. Cardiol., 1991; 68: 681-684.Goy J.-J., Fromer M,., Kappenberger L. Electrophysiologic effects of intravenous propafenone at rest, during isoproterenol infusion and during exercise in the Wolff-Parkinson-White syndrome. – Amer. J. Cardiol., 1991; 68: 681-684.Gaita F., Guistetto C., Riccardi R., Brusca A. Wolff-Parkinson-White syndrome: Identification and management. – Drugs, 1992; 43: 185- 200.Gaita F., Guistetto C., Riccardi R., Brusca A. Wolff-Parkinson-White syndrome: Identification and management. – Drugs, 1992; 43: 185- 200.Cheriex E.C., Krijne R., Brugada P. et al. Lack of clinically significant β-blocking effect of propafenone. – Europ. Heart J., 1987; 8 (1):53-56.Cheriex E.C., Krijne R., Brugada P. et al. Lack of clinically significant β-blocking effect of propafenone. – Europ. Heart J., 1987; 8 (1):53-56.Malfatto G., Pessano P., Zaza A. et al. Experimental evidence for beta-blocking properties of propafenone and for their potential clinical relevance. — Europ. Heart J., 1993; 14: 1253-1257.Malfatto G., Pessano P., Zaza A. et al. Experimental evidence for beta-blocking properties of propafenone and for their potential clinical relevance. — Europ. Heart J., 1993; 14: 1253-1257.Boriani G., Capucci A., Strocchi E. et al. β-blocking properties of propafenone in extensive oxidisers; A study on heart rate behaviour during Holter monitoring – Drug Invest., 1993; 6 (1): 25-32.Boriani G., Capucci A., Strocchi E. et al. β-blocking properties of propafenone in extensive oxidisers; A study on heart rate behaviour during Holter monitoring – Drug Invest., 1993; 6 (1): 25-32.Bigot M.-C., Debruyne D., Bonnefoy L. et al. Serum digoxin levels related to plasma propafenone levels during concomitant treament. – J. Clin. Pharmacol., 1991; 31: 521-526.Bigot M.-C., Debruyne D., Bonnefoy L. et al. Serum digoxin levels related to plasma propafenone levels during concomitant treament. – J. Clin. Pharmacol., 1991; 31: 521-526.Lee B.L., Dohrmann M.L. Theophylline toxicity after propafenone: Evidence for drug interaction. – Clin. Pharmacol. Therapy, 1991; 52: 353-355.Lee B.L., Dohrmann M.L. Theophylline toxicity after propafenone: Evidence for drug interaction. – Clin. Pharmacol. Therapy, 1991; 52: 353-355.Kishore A.G.R., Camm A.J. Guidelines for the use of propafenone in treating supraventricular arrhythmias. – Drugs, 1995; 50 (2): 250-262.Kishore A.G.R., Camm A.J. Guidelines for the use of propafenone in treating supraventricular arrhythmias. – Drugs, 1995; 50 (2): 250-262.

The authors declare that there are no conflicts of interest present.